211 related articles for article (PubMed ID: 35570581)
1. B-Cell-Directed Therapies: A New Era in Multiple Sclerosis Treatment.
Kanatas P; Stouras I; Stefanis L; Stathopoulos P
Can J Neurol Sci; 2023 May; 50(3):355-364. PubMed ID: 35570581
[TBL] [Abstract][Full Text] [Related]
2. Therapies for multiple sclerosis targeting B cells.
Milo R
Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
[TBL] [Abstract][Full Text] [Related]
3. B cells in multiple sclerosis therapy-A comprehensive review.
Rahmanzadeh R; Weber MS; Brück W; Navardi S; Sahraian MA
Acta Neurol Scand; 2018 Jun; 137(6):544-556. PubMed ID: 29512131
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD20 in multiple sclerosis - review of current treatment strategies.
Chmielewska N; Szyndler J
Neurol Neurochir Pol; 2023; 57(3):235-242. PubMed ID: 36999373
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis.
Cotchett KR; Dittel BN; Obeidat AZ
Mult Scler Relat Disord; 2021 Apr; 49():102787. PubMed ID: 33516134
[TBL] [Abstract][Full Text] [Related]
6. Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
Delgado SR; Faissner S; Linker RA; Rammohan K
J Neurol; 2024 Apr; 271(4):1515-1535. PubMed ID: 37906325
[TBL] [Abstract][Full Text] [Related]
7. B cell-directed therapies in multiple sclerosis.
Gasperi C; Stüve O; Hemmer B
Neurodegener Dis Manag; 2016; 6(1):37-47. PubMed ID: 26782316
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies targeting B-cells in multiple sclerosis.
Milo R
Autoimmun Rev; 2016 Jul; 15(7):714-8. PubMed ID: 26970489
[TBL] [Abstract][Full Text] [Related]
9. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
Graf J; Mares J; Barnett M; Aktas O; Albrecht P; Zamvil SS; Hartung HP
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33406479
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
[TBL] [Abstract][Full Text] [Related]
11. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
Ancau M; Berthele A; Hemmer B
Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
[TBL] [Abstract][Full Text] [Related]
12. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis.
Torke S; Weber MS
Expert Opin Investig Drugs; 2020 Oct; 29(10):1143-1150. PubMed ID: 32772592
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives.
Margoni M; Preziosa P; Filippi M; Rocca MA
J Neurol; 2022 Mar; 269(3):1316-1334. PubMed ID: 34382120
[TBL] [Abstract][Full Text] [Related]
15. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
Saberi D; Geladaris A; Dybowski S; Weber MS
Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
[TBL] [Abstract][Full Text] [Related]
16. Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis.
Ho S; Oswald E; Wong HK; Vural A; Yilmaz V; Tüzün E; Türkoğlu R; Straub T; Meinl I; Thaler F; Kümpfel T; Meinl E; Mader S
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36702538
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.
Lehmann-Horn K; Kinzel S; Weber MS
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946620
[TBL] [Abstract][Full Text] [Related]
18. The potential role of B cell-targeted therapies in multiple sclerosis.
Boster A; Ankeny DP; Racke MK
Drugs; 2010 Dec; 70(18):2343-56. PubMed ID: 21142258
[TBL] [Abstract][Full Text] [Related]
19. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
20. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
Carnero Contentti E; Correale J
Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
